Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Long-Term Deferred Tax (2016 - 2019)

Niagen Bioscience (NAGE) has disclosed Long-Term Deferred Tax for 4 consecutive years, with $218000.0 as the latest value for Q4 2019.

  • On a quarterly basis, Long-Term Deferred Tax fell 99.01% to $218000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $218000.0, a 99.01% decrease, with the full-year FY2019 number at $218000.0, down 99.01% from a year prior.
  • Long-Term Deferred Tax was $218000.0 for Q4 2019 at Niagen Bioscience, down from $22.1 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $22.1 million in Q4 2018 to a low of $144000.0 in Q4 2017.
  • A 4-year average of $7.7 million and a median of $399000.0 in 2016 define the central range for Long-Term Deferred Tax.
  • Peak YoY movement for Long-Term Deferred Tax: skyrocketed 15225.69% in 2018, then crashed 99.01% in 2019.
  • Niagen Bioscience's Long-Term Deferred Tax stood at $399000.0 in 2016, then tumbled by 63.91% to $144000.0 in 2017, then surged by 15225.69% to $22.1 million in 2018, then plummeted by 99.01% to $218000.0 in 2019.
  • Per Business Quant, the three most recent readings for NAGE's Long-Term Deferred Tax are $218000.0 (Q4 2019), $22.1 million (Q4 2018), and $144000.0 (Q4 2017).